Established in 2020 the European Expert Group on Orphan Drug Incentives (OD Expert Group) brings together representatives of the broad rare diseases community, including researchers, academia, patient representatives, members of the investor community, rare disease companies and trade associations.
This group aims to become the source of ground-breaking ideas and potential solutions that will provide input to the OMP Regulation Evaluation. The initiative is led by a steering group composed of EURORDIS, The Voice of Rare Disease Patients in Europe and the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE) representing several companies focused on finding new therapies for rare disease.
The group is co-chaired by former MEP Renate Sommer and Professor Maurizio Scarpa, Coordinator of MetaBERN. The following EUCOPE member companies are sponsoring and providing expertise to the initiative: Alexion, Biogen, Bristol Myers Squibb, Chiesi, PTC Therapeutics and Takeda.